Vertex’s executive chairman: Here’s how we got our drug-trial… | HappeningNow.news

Business & Economy · 6 views

Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20%

More bets don’t necessarily produce more successes

Source AI Summary Published 1h 22m ago Brief Under 1 min brief
Story intelligence
Coverage Single outlet Single-outlet story
Views 6 Community interest
Brief read Under 1 min brief 87 words

AI Summary

Vertex’s executive chairman explained that the company’s drug‑trial success rate has risen above 70%, far higher than the industry average of 10% to 20%. He attributed this to a strategy of making fewer, smarter bets rather than many broad R&D investments. The approach focuses on targeted, high‑confidence projects, reducing the typical 10‑15‑year development cycle and the 90% failure rate that plagues the sector. This shift aims to improve efficiency and outcomes in a field where even large firms can experience multiple trial failures in a single week.

AI summaries can be wrong sometimes—always verify important details using the source article.

How AI & Automation are used
Read original at Fortune

More from Business & Economy

Continue reading recent Business & Economy coverage

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page